Polycystic Ovary Syndrome - Targeting the Sympathetic Nervous System to Improve Outcomes
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Microneurography
研究概览
简要总结
Polycystic ovary syndrome affects a striking 9-18% of Australian reproductive aged women and has been associated with a number of metabolic abnormalities.
Given the strong correlation between metabolic abnormalities and increased sympathetic activity, we hypothesise that reducing this activity using medication (moxonidine) can help improve the metabolic abnormalities, and therefore improve outcomes in polycystic ovary syndrome.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Overweight and class I obese pre-menopausal women
- •Diagnosis of PCOS by Rotterdam criteria
排除标准
- •Any current medication
- •pregnancy or the desire to become pregnant
- •BMI > 35
- •a history of type I diabetes, secondary hypertension not due to PCOS
- •cardiovascular, cerebrovascular, liver or thyroid disease
- •severe mental illness.
研究组 & 干预措施
Active
干预措施: Moxonidine (Drug)
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Microneurography
时间窗: 3 months
Microneurography is a technique developed to measure the sympathetic activitiy directly from the peroneal nerve. Microneurography will be performed at baseline visit and at 3 months follow up visit.
次要结局
- Blood biochemistry measurement(3 months)
- Oral glucose tolerance test(3 months)
研究者
Markus Schlaich
Associate Professor
Baker Heart and Diabetes Institute